The profibrotic role of endothelin-1: Is the door still open for the treatment of fibrotic diseases?

Life Sciences

Volumn 118, Issue 2, 2014, Pages 156-164

  Rodríguez Pascual, Fernando ^a   Busnadiego, Oscar ^a   González Santamaría, José ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Endothelin; Endothelin receptor antagonists; Extracellular matrix; Fibrosis

Indexed keywords

ENDOTHELIN 1;

EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HUMAN; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN SYNTHESIS; REVIEW; SKIN FIBROSIS; VASCULAR DISEASE; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; GENETICS; METABOLISM;

ANIMALS; ENDOTHELIN-1; FIBROSIS; HUMANS; MODELS, BIOLOGICAL; ORGAN SPECIFICITY;

EID: 84892641923     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2013.12.024     Document Type: Review

References (122)

1. Abraham, D.J., Vancheeswaran, R., Dashwood, M.R., Rajkumar, V.S., Pantelides, P., Xu, S.W., et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 151 (1997), 831–841.
2. Adiarto, S., Heiden, S., Vignon-Zellweger, N., Nakayama, K., Yagi, K., Yanagisawa, M., et al. ET-1 from endothelial cells is required for complete angiotensin II-induced cardiac fibrosis and hypertrophy. Life Sci 91 (2012), 651–657.
3. Ahmedat, A.S., Warnken, M., Seemann, W.K., Mohr, K., Kostenis, E., Juergens, U.R., et al. Pro-fibrotic processes in human lung fibroblasts are driven by an autocrine/paracrine endothelinergic system. Br J Pharmacol 168 (2013), 471–487.
4. Alvarez, D., Briassouli, P., Clancy, R.M., Zavadil, J., Reed, J.H., Abellar, R.G., et al. A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. J Biol Chem 286 (2011), 30444–30454.
5. Amiri, F., Virdis, A., Neves, M.F., Iglarz, M., Seidah, N.G., Touyz, R.M., et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110 (2004), 2233–2240.
6. Amiri, F., Ko, E.A., Javeshghani, D., Reudelhuber, T.L., Schiffrin, E.L., Deleterious combined effects of salt-loading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function in mice. J Hypertens 28 (2010), 1243–1251.
7. Ammarguellat, F., Larouche, I., Schiffrin, E.L., Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation 103 (2001), 319–324.
8. Anand, I., McMurray, J., Cohn, J.N., Konstam, M.A., Notter, T., Quitzau, K., et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004), 347–354.
9. Arai, H., Hori, S., Aramori, I., Ohkubo, H., Nakanishi, S., Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348 (1990), 730–732.
10. Bateman, J.F., Boot-Handford, R.P., Lamande, S.R., Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations. Nat Rev Genet 10 (2009), 173–183.
11. Biernacka, A., Dobaczewski, M., Frangogiannis, N.G., TGF-beta signaling in fibrosis. Growth Factors 29 (2011), 196–202.
12. Binai, N., O'Reilly, S., Griffiths, B., van Laar, J.M., Hugle, T., Differentiation potential of CD14 + monocytes into myofibroblasts in patients with systemic sclerosis. PLoS One, 7, 2012, e33508.
13. Campanholle, G., Ligresti, G., Gharib, S.A., Duffield, J.S., Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Am J Physiol Cell Physiol 304 (2013), C591–C603.
14. Cerione, R.A., Strulovici, B., Benovic, J.L., Strader, C.D., Caron, M.G., Lefkowitz, R.J., Reconstitution of beta-adrenergic receptors in lipid vesicles: affinity chromatography-purified receptors confer catecholamine responsiveness on a heterologous adenylate cyclase system. Proc Natl Acad Sci U S A 80 (1983), 4899–4903.
15. Dhaun, N., MacIntyre, I.M., Kerr, D., Melville, V., Johnston, N.R., Haughie, S., et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 57 (2011), 772–779.
16. Dhaun, N., Webb, D.J., Kluth, D.C., Endothelin-1 and the kidney — beyond BP. Br J Pharmacol 167 (2012), 720–731.
17. Feng, H.Q., Weymouth, N.D., Rockey, D.C., Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease. Am J Physiol Gastrointest Liver Physiol 297 (2009), G27–G33.
18. Fligny, C., Duffield, J.S., Activation of pericytes: recent insights into kidney fibrosis and microvascular rarefaction. Curr Opin Rheumatol 25 (2013), 78–86.
19. Fligny, C., Barton, M., Tharaux, P.L., Endothelin and podocyte injury in chronic kidney disease. Contrib Nephrol 172 (2011), 120–138.
20. Friedman, S.L., Hepatic fibrosis—overview. Toxicology 254 (2008), 120–129.
21. Furchgott, R.F., Zawadzki, J.V., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980), 373–376.
22. Gabbiani, G., The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 200 (2003), 500–503.
23. Georgoulas, S., Dahlmann-Noor, A., Brocchini, S., Khaw, P.T., Modulation of wound healing during and after glaucoma surgery. Prog Brain Res 173 (2008), 237–254.
24. Gregan, B., Schaefer, M., Rosenthal, W., Oksche, A., Fluorescence resonance energy transfer analysis reveals the existence of endothelin-A and endothelin-B receptor homodimers. J Cardiovasc Pharmacol 44:Suppl. 1 (2004), S30–S33.
25. Guarda, E., Katwa, L.C., Myers, P.R., Tyagi, S.C., Weber, K.T., Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 27 (1993), 2130–2134.
26. Guo, C.Y., Wu, J.Y., Wu, Y.B., Zhong, M.Z., Lu, H.M., Effects of endothelin-1 on hepatic stellate cell proliferation, collagen synthesis and secretion, intracellular free calcium concentration. World J Gastroenterol 10 (2004), 2697–2700.
27. Hafizi, S., Wharton, J., Chester, A.H., Yacoub, M.H., Profibrotic effects of endothelin-1 via the ETA receptor in cultured human cardiac fibroblasts. Cell Physiol Biochem 14 (2004), 285–292.
28. Hartopo, A.B.., Emoto, N., Vignon-Zellweger, N., Suzuki, Y., Yagi, K., Nakayama, K., et al. Endothelin-converting enzyme-1 gene ablation attenuates pulmonary fibrosis via CGRP-cAMP/EPAC1 pathway. Am J Respir Cell Mol Biol 48 (2013), 465–476.
29. He, C., Miao, X., Li, J., Qi, H., Angiotensin II induces endothelin-1 expression in human hepatic stellate cells. Dig Dis Sci 58 (2013), 2542–2549.
30. Herman, W.H., Emancipator, S.N., Rhoten, R.L., Simonson, M.S., Vascular and glomerular expression of endothelin-1 in normal human kidney. Am J Physiol 275 (1998), F8–F17.
31. Hieda, H.S., Gomez-Sanchez, C.E., Hypoxia increases endothelin release in bovine endothelial cells in culture, but epinephrine, norepinephrine, serotonin, histamine and angiotensin II do not. Life Sci 47 (1990), 247–251.
32. Hinz, B., The myofibroblast: paradigm for a mechanically active cell. J Biomech 43 (2010), 146–155.
33. Hocher, B., Thone-Reineke, C., Rohmeiss, P., Schmager, F., Slowinski, T., Burst, V., et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99 (1997), 1380–1389.
34. Horowitz, J.C., Ajayi, I.O., Kulasekaran, P., Rogers, D.S., White, J.B., Townsend, S.K., et al. Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Int J Biochem Cell Biol 44 (2012), 158–169.
35. Horstmeyer, A., Licht, C., Scherr, G., Eckes, B., Krieg, T., Signalling and regulation of collagen I synthesis by ET-1 and TGF-beta1. FEBS J 272 (2005), 6297–6309.
36. Hu, J., Discher, D.J., Bishopric, N.H., Webster, K.A., Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun 245 (1998), 894–899.
37. Humbert, M., Segal, E.S., Kiely, D.G., Carlsen, J., Schwierin, B., Hoeper, M.M., Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 30 (2007), 338–344.
38. Ikeda, T., Ohta, H., Okada, M., Kawai, N., Nakao, R., Siegl, P.K., et al. Antihypertensive effects of a mixed endothelin-A- and -B-receptor antagonist, J-104132, were augmented in the presence of an AT1-receptor antagonist, MK-954. J Cardiovasc Pharmacol 36 (2000), S337–S341.
39. Inoue, A., Yanagisawa, M., Takuwa, Y., Mitsui, Y., Kobayashi, M., Masaki, T., The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 264 (1989), 14954–14959.
40. Ivanova, L., Butt, M.J., Matsell, D.G., Mesenchymal transition in kidney collecting duct epithelial cells. Am J Physiol Ren Physiol 294 (2008), F1238–F1248.
41. Jain, R., Shaul, P.W., Borok, Z., Willis, B.C., Endothelin-1 induces alveolar epithelial–mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. Am J Respir Cell Mol Biol 37 (2007), 38–47.
42. Jugdutt, B.I., Dhalla, N.S., Jugdutt, B., Regulation of fibrosis after myocardial infarction: implications for ventricular remodeling. Cardiac remodeling, 2013, Springer, New York, 525–545.
43. Kalk, P., Sharkovska, Y., Kashina, E., von Websky, K., Relle, K., Pfab, T., et al. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension 57 (2011), 755–763.
44. Katritch, V., Cherezov, V., Stevens, R.C., Structure–function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 53 (2013), 531–556.
45. Katwa, L.C., Cardiac myofibroblasts isolated from the site of myocardial infarction express endothelin de novo. Am J Physiol Heart Circ Physiol 285 (2003), H1132–H1139.
46. Kawaguchi, Y., Suzuki, K., Hara, M., Hidaka, T., Ishizuka, T., Kawagoe, M., et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 53 (1994), 506–510.
47. Kawana, M., Lee, M.E., Quertermous, E.E., Quertermous, T., Cooperative interaction of GATA-2 and AP1 regulates transcription of the endothelin-1 gene. Mol Cell Biol 15 (1995), 4225–4231.
48. Kedzierski, R.M., Yanagisawa, M., Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41 (2001), 851–876.
49. Kennedy, L., Shi-Wen, X., Carter, D.E., Abraham, D.J., Leask, A., Fibroblast adhesion results in the induction of a matrix remodeling gene expression program. Matrix Biol 27 (2008), 274–281.
50. Khimji, A.K., Rockey, D.C., Endothelin and hepatic wound healing. Pharmacol Res 63 (2011), 512–518.
51. King, T.E. Jr., Bosentan for idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 9 (2008), 1171–1179.
52. King, T.E., Behr, J., Brown, K.K., du Bois, R.M., Lancaster, L., de Andrade, J.A., et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177 (2008), 75–81.
53. King, T.E. Jr., Brown, K.K., Raghu, G., du Bois, R.M., Lynch, D.A., Martinez, F., et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184 (2011), 92–99.
54. Kis, K., Liu, X., Hagood, J.S., Myofibroblast differentiation and survival in fibrotic disease. Expert Rev Mol Med, 13, 2011, e27.
55. Kohan, D.E., Pritchett, Y., Molitch, M., Wen, S., Garimella, T., Audhya, P., et al. Addition of atrasentan to renin–angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22 (2011), 763–772.
56. Kohan, D.E., Cleland, J.G., Rubin, L.J., Theodorescu, D., Barton, M., Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?. Life Sci 91 (2012), 528–539.
57. Kolettis, T.M., Barton, M., Langleben, D., Matsumura, Y., Endothelin in coronary artery disease and myocardial infarction. Cardiol Rev 21 (2013), 249–256.
58. Korn, J.H., Mayes, M., Matucci Cerinic, M., Rainisio, M., Pope, J., Hachulla, E., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 (2004), 3985–3993.
59. Kourembanas, S., Marsden, P.A., McQuillan, L.P., Faller, D.V., Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 88 (1991), 1054–1057.
60. Kurihara, H., Yoshizumi, M., Sugiyama, T., Takaku, F., Yanagisawa, M., Masaki, T., et al. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 159 (1989), 1435–1440.
61. Lagares, D., Garcia-Fernandez, R.A., Jimenez, C.L., Magan-Marchal, N., Busnadiego, O., Lamas, S., et al. Endothelin 1 contributes to the effect of transforming growth factor beta1 on wound repair and skin fibrosis. Arthritis Rheum 62 (2010), 878–889.
62. Lagares, D., Busnadiego, O., Garcia-Fernandez, R.A., Kapoor, M., Liu, S., Carter, D.E., et al. Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum 64 (2012), 1653–1664.
63. Lagares, D., Busnadiego, O., Garcia-Fernandez, R.A., Lamas, S., Rodriguez-Pascual, F., Adenoviral gene transfer of endothelin-1 in the lung induces pulmonary fibrosis through the activation of focal adhesion kinase. Am J Respir Cell Mol Biol 47 (2012), 834–842.
64. Lehrke, I., Waldherr, R., Ritz, E., Wagner, J., Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol 12 (2001), 2321–2329.
65. Lenna, S., Chrobak, I., Farina, G.A., Rodriguez-Pascual, F., Lamas, S., Lafyatis, R., et al. HLA-B35 and dsRNA induce endothelin-1 via activation of ATF4 in human microvascular endothelial cells. PLoS One, 8, 2013, e56123.
66. Li, D., Yang, P., Li, H., Cheng, P., Zhang, L., Wei, D., et al. MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. Life Sci 91 (2012), 440–447.
67. Luscher, T.F., Barton, M., Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102 (2000), 2434–2440.
68. Mann, J.F.E., Green, D., Jamerson, K., Ruilope, L.M., Kuranoff, S.J., Littke, T., et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21 (2010), 527–535.
69. Mansoor, A.M., Honda, M., Saida, K., Ishinaga, Y., Kuramochi, T., Maeda, A., et al. Endothelin induced collagen remodeling in experimental pulmonary hypertension. Biochem Biophys Res Commun 215 (1995), 981–986.
70. Masaki, T., Historical review: endothelin. Trends Pharmacol Sci 25 (2004), 219–224.
71. Matucci-Cerinic, M., Denton, C.P., Furst, D.E., Mayes, M.D., Hsu, V.M., Carpentier, P., et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70 (2011), 32–38.
72. Mishra, R., Leahy, P., Simonson, M.S., Gene expression profile of endothelin-1-induced growth in glomerular mesangial cells. Am J Physiol Cell Physiol 285 (2003), C1109–C1115.
73. Miyauchi, T., Masaki, T., Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 61 (1999), 391–415.
74. Möller, S., Uddman, R., Granström, B., Edvinsson, L., Altered ratio of endothelin ETA- and ETB receptor mRNA in bronchial biopsies from patients with asthma and chronic airway obstruction. Eur J Pharmacol 365 (1999), R1–R3.
75. Morigi, M., Buelli, S., Zanchi, C., Longaretti, L., Macconi, D., Benigni, A., et al. Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 169 (2006), 1965–1975.
76. Nguyen, V.A., Eisendle, K., Gruber, I., Hugl, B., Reider, D., Reider, N., Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford) 49 (2010), 583–587.
77. Nishida, M., Onohara, N., Sato, Y., Suda, R., Ogushi, M., Tanabe, S., et al. Galpha12/13-mediated up-regulation of TRPC6 negatively regulates endothelin-1-induced cardiac myofibroblast formation and collagen synthesis through nuclear factor of activated T cells activation. J Biol Chem 282 (2007), 23117–23128.
78. Odoux, C., Crestani, B., Lebrun, G.L., Rolland, C., Aubin, P., Seta, N., et al. Endothelin-1 secretion by alveolar macrophages in systemic sclerosis. Am J Respir Crit Care Med 156 (1997), 1429–1435.
79. Park, S.H., Saleh, D., Giaid, A., Michel, R.P., Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 156 (1997), 600–608.
80. Piacentini, L., Gray, M., Honbo, N.Y., Chentoufi, J., Bergman, M., Karliner, J.S., Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol 32 (2000), 565–576.
81. Piera-Velazquez, S., Li, Z., Jimenez, S.A., Role of endothelial–mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 179 (2011), 1074–1080.
82. Prasad, S.K., Dargie, H.J., Smith, G.C., Barlow, M.M., Grothues, F., Groenning, B.A., et al. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. Heart 92 (2006), 798–803.
83. Raghu, G., Behr, J., Brown, K.K., Egan, J.J., Kawut, S.M., Flaherty, K.R., et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 158 (2013), 641–649.
84. Raghu, G., Million-Rousseau, R., Morganti, A., Perchenet, L., Behr, J., Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 42 (2013), 1622–1632.
85. Rao, V.R., Krishnamoorthy, R.R., Yorio, T., Endothelin-1 mediated regulation of extracellular matrix collagens in cells of human lamina cribrosa. Exp Eye Res 86 (2008), 886–894.
86. Reimunde, F.M., Castanares, C., Redondo-Horcajo, M., Lamas, S., Rodriguez-Pascual, F., Endothelin-1 expression is strongly repressed by AU-rich elements in the 3′-untranslated region of the gene. Biochem J 387 (2005), 763–772.
87. Richeldi, L., du Bois, R.M., Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Rev Respir Med 5 (2011), 473–481.
88. Rizvi, M.A., Katwa, L., Spadone, D.P., Myers, P.R., The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. J Mol Cell Cardiol 28 (1996), 243–252.
89. Rockey, D.C., Chung, J.J., Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest 98 (1996), 1381–1388.
90. Rockey, D.C., Fouassier, L., Chung, J.J., Carayon, A., Vallee, P., Rey, C., et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 27 (1998), 472–480.
91. Rodriguez-Pascual, F., Redondo-Horcajo, M., Lamas, S., Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression. Circ Res 92 (2003), 1288–1295.
92. Rodriguez-Pascual, F., Reimunde, F.M., Redondo-Horcajo, M., Lamas, S., Transforming growth factor-beta induces endothelin-1 expression through activation of the Smad signaling pathway. J Cardiovasc Pharmacol 44:Suppl. 1 (2004), S39–S42.
93. Rodriguez-Pascual, F., Busnadiego, O., Lagares, D., Lamas, S., Role of endothelin in the cardiovascular system. Pharmacol Res 63 (2011), 463–472.
94. Rodriguez-Vita, J., Ruiz-Ortega, M., Ruperez, M., Esteban, V., Sanchez-Lopez, E., Plaza, J.J., et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res 97 (2005), 125–134.
95. Ruiz-Ortega, M., Rodriguez-Vita, J., Sanchez-Lopez, E., Carvajal, G., Egido, J., TGF-beta signaling in vascular fibrosis. Cardiovasc Res 74 (2007), 196–206.
96. Sakamoto, H., Sasaki, S., Hirata, Y., Imai, T., Ando, K., Ida, T., et al. Production of endothelin-1 by rat cultured mesangial cells. Biochem Biophys Res Commun 169 (1990), 462–468.
97. Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K., et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348 (1990), 732–735.
98. Saleh, D., Furukawa, K., Tsao, M.S., Maghazachi, A., Corrin, B., Yanagisawa, M., et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 16 (1997), 187–193.
99. Sandrin, L., Fourquet, B., Hasquenoph, J.M., Yon, S., Fournier, C., Mal, F., et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29 (2003), 1705–1713.
100. Shafiei, M.S., Rockey, D.C., The function of integrin-linked kinase in normal and activated stellate cells: implications for fibrogenesis in wound healing. Lab Invest 92 (2012), 305–316.
101. Shi-Wen, X., Denton, C.P., Dashwood, M.R., Holmes, A.M., Bou-Gharios, G., Pearson, J.D., et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 116 (2001), 417–425.
102. Shi-Wen, X., Chen, Y., Denton, C.P., Eastwood, M., Renzoni, E.A., Bou-Gharios, G., et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 15 (2004), 2707–2719.
103. Shi-Wen, X., Rodriguez-Pascual, F., Lamas, S., Holmes, A., Howat, S., Pearson, J.D., et al. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 26 (2006), 5518–5527.
104. Shi-wen, X., Kennedy, L., Renzoni, E.A., Bou-Gharios, G., du Bois, R.M., Black, C.M., et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum 56 (2007), 4189–4194.
105. Simonson, M.S., Ismail-Beigi, F., Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. J Biol Chem 286 (2011), 11003–11008.
106. Steen, V., Denton, C.P., Pope, J.E., Matucci-Cerinic, M., Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 48:Suppl. 3 (2009), iii19–iii24.
107. Stow, L.R., Jacobs, M.E., Wingo, C.S., Cain, B.D., Endothelin-1 gene regulation. FASEB J 25 (2010), 16–28.
108. Sun, G., Stacey, M.A., Bellini, A., Marini, M., Mattoli, S., Endothelin-1 induces bronchial myofibroblast differentiation. Peptides 18 (1997), 1449–1451.
109. Sutsch, G., Kiowski, W., Yan, X.W., Hunziker, P., Christen, S., Strobel, W., et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98 (1998), 2262–2268.
110. Tripathi, D., Therapondos, G., Ferguson, J.W., Newby, D.E., Webb, D.J., Hayes, P.C., Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. Gut 55 (2006), 1290–1295.
111. Trojanowska, M., Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 6 (2010), 453–460.
112. Uguccioni, M., Pulsatelli, L., Grigolo, B., Facchini, A., Fasano, L., Cinti, C., et al. Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol 48 (1995), 330–334.
113. Vancheeswaran, R., Azam, A., Black, C., Dashwood, M.R., Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 21 (1994), 1268–1276.
114. Varga, J., Brenner, D.A., Phan, S.H., Fibrosis research: methods and protocols. 2005, Humana Press Inc., Totowa, NJ.
115. Wynn, T.A., Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117 (2007), 524–529.
116. Wynn, T.A., Cellular and molecular mechanisms of fibrosis. J Pathol 214 (2008), 199–210.
117. Xu, S., Denton, C.P., Holmes, A., Dashwood, M.R., Abraham, D.J., Black, C.M., Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 31:Suppl. 1 (1998), S360–S363.
118. Xu, S.W., Howat, S.L., Renzoni, E.A., Holmes, A., Pearson, J.D., Dashwood, M.R., et al. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem 279 (2004), 23098–23103.
119. Yamashita, K., Discher, D.J., Hu, J., Bishopric, N.H., Webster, K.A., Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J Biol Chem 276 (2001), 12645–12653.
120. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988), 411–415.
121. Yeligar, S., Tsukamoto, H., Kalra, V.K., Ethanol-induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxia-inducible factor-1alpha and microrNA-199. J Immunol 183 (2009), 5232–5243.
122. Zhan, S., Rockey, D.C., Tumor necrosis factor alpha stimulates endothelin-1 synthesis in rat hepatic stellate cells in hepatic wound healing through a novel IKK/JNK pathway. Exp Cell Res 317 (2011), 1040–1048.